IP Verse

Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated Disorders - EP3310760B8

PatentPatent Analysis

EP3310760

ARENA PHARMACEUTICALS
Application Number
EP16734529A
Filing Date
Jun 21, 2016
Status
Granted And Under Opposition
Aug 12, 2022
Grant Date
Oct 19, 2022
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3242666B9
EP3801459B1
EP3582814B1

Bibliography

The patent EP3310760B8 was granted to Arena Pharmaceuticals on Oct 19, 2022 following the initial filing on Jun 21, 2016 under the application number EP16734529A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZJun 14, 2023ADMISSIBLE
SCORPIOJun 14, 2023ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents